Abstract
The escalating prevalence of multidrug-resistant (MDR) Acinetobacter baumannii presents a formidable challenge to global healthcare, necessitating innovative therapeutic strategies. This review explores the critical role of clinical microbiology in the detection, surveillance, and management of MDR A. baumannii infections, underscoring the importance of accurate diagnostics and infection control. Concurrently, the pyrazole heterocyclic scaffold emerges as a promising molecular framework in the development of novel antibacterial agents, owing to its versatile chemical properties and demonstrated bioactivity against resistant strains. MDR A. baumannii has emerged as a major global health threat, with prevalence rates exceeding 60% in many hospital-acquired infections, thereby underscoring the urgent need for novel therapeutic approaches. This review provides a comprehensive analysis of recent advances in the development of pyrazole-based scaffolds, emphasizing structure-activity relationship (SAR) insights that rational design and fine-tuning of antibacterial potency and target selectivity. This integrated perspective highlights the synergy between clinical microbiological approaches and medicinal chemistry advancements, contributing to the design of more effective antimicrobial agents against the increasingly resistant and clinically significant pathogen A. baumannii.